Mitochondrial biogenesis — how cells build more power plants, and why it fades with age

A mitochondrion is, functionally, a power plant. Inside its folded inner membrane sits the electron transport chain, a series of protein complexes that pass electrons down an energy gradient and use the released energy to pump protons, creating a voltage that drives the synthesis of ATP — the molecule that powers nearly everything a cell does. A muscle cell working hard, a neuron firing, a heart muscle contracting tens of thousands of times a day: all of it runs on ATP, and nearly all of that ATP comes from mitochondria. It follows that a cell's energetic capacity depends heavily on how many mitochondria it has and how well they work. Tissues with high energy demand — heart, skeletal muscle, brain — are densely packed with them. And because demand changes over a lifetime, with training, and with the metabolic state of the body, cells need a way to adjust the size of their mitochondrial fleet. That adjustment, on the building side, is mitochondrial biogenesis.

Building a mitochondrion is a genuinely complicated manufacturing problem, because a mitochondrion is a hybrid structure assembled from two separate genomes. The great majority of mitochondrial proteins are encoded in the nucleus, made in the main body of the cell, and imported across the mitochondrial membranes. A small but essential set is encoded by the mitochondrion's own DNA and made inside the organelle. To build new mitochondria, a cell has to coordinate both genomes at once — turning on hundreds of nuclear genes and ramping up replication and transcription of mitochondrial DNA in synchrony. The molecule that orchestrates this coordination is PGC-1alpha, formally peroxisome proliferator-activated receptor gamma coactivator 1-alpha, discovered in the laboratory of Bruce Spiegelman in the late 1990s. PGC-1alpha is a transcriptional coactivator: it does not bind DNA directly to flip a single switch but instead partners with a range of transcription factors and amplifies their activity, acting as a conductor that brings the whole orchestra of biogenesis genes in at once. It switches on factors such as NRF-1 and NRF-2 that drive nuclear-encoded mitochondrial genes, and TFAM, which travels into the mitochondrion to drive replication and transcription of its DNA. When biologists call PGC-1alpha the master regulator of mitochondrial biogenesis, this coordinating role is what they mean.

The obvious next question is what turns PGC-1alpha on, and the answer is that the cell links biogenesis to its energy status through two sensors. The first is AMPK, AMP-activated protein kinase, the cell's low-fuel gauge. When a cell expends energy faster than it can replace it, ATP is broken down to ADP and AMP, and the rising ratio of AMP to ATP activates AMPK. Activated AMPK is, in effect, an alarm that says the cell is running short on energy and must both conserve and expand capacity; among its many actions, it activates PGC-1alpha. The second sensor is SIRT1, a member of the sirtuin family of enzymes, which responds not to the energy charge directly but to the availability of NAD+, a coenzyme whose ratio to its reduced form, NADH, reflects the metabolic state of the cell. When NAD+ is abundant — as it is during fasting, caloric restriction, and exercise — SIRT1 becomes active and chemically modifies PGC-1alpha in a way that further switches it on. AMPK and SIRT1 are interconnected; AMPK activity tends to raise NAD+ and thereby feed SIRT1, so the two sensors reinforce each other. Both report the same underlying message — the cell is being asked to do more with less — and both converge on PGC-1alpha to expand the mitochondrial fleet in response.

This explains why exercise is the dominant trigger of mitochondrial biogenesis, and why it is not even close. A bout of endurance or high-intensity exercise is precisely the stimulus this machinery evolved to read: a sharp, sustained energy demand that drains ATP, raises AMP, shifts the NAD+ ratio, raises calcium signaling in working muscle, and generates a transient burst of reactive oxygen species. Every one of those signals feeds into AMPK, SIRT1, and the calcium-sensitive kinases, and all of them push PGC-1alpha. Repeated over weeks of training, this drives a measurable expansion of mitochondrial content in skeletal muscle — one of the best-documented adaptations in all of exercise physiology, the reason a trained endurance athlete can have markedly higher muscle mitochondrial density than a sedentary person. No pill in the research literature reproduces the breadth and reliability of this response. Caloric restriction and fasting engage the same pathways through the NAD+/SIRT1 arm, cold exposure recruits PGC-1alpha in fat and muscle, and these are real and interesting, but exercise remains the reference standard against which every other intervention is measured.

The longevity relevance comes from what happens to all of this with age. Mitochondrial content and function decline over the decades — fewer mitochondria per cell in many tissues, reduced efficiency of the electron transport chain, accumulation of damage in mitochondrial DNA and membranes, and a blunted biogenic response to the same stimuli that drove robust adaptation in youth. PGC-1alpha expression itself tends to fall with age. The consequences are felt as the everyday physiology of getting older: the fatigue, the reduced exercise tolerance, the loss of metabolic flexibility — the ability to switch cleanly between burning fat and glucose — and the contribution to sarcopenia and frailty. Mitochondrial dysfunction is one of the recognized hallmarks of aging, and it intersects most of the others, from chronic inflammation to cellular senescence, because failing mitochondria leak signals that the rest of the cell reads as stress. This is why "support your mitochondria" has become a longevity refrain. The underlying observation is sound: an aging body that maintained youthful mitochondrial capacity would, in principle, retain much of its energy and resilience.

But here is the distinction that most of the marketing blurs, and it is the single most important idea for thinking clearly about mitochondrial interventions. Biogenesis — making more mitochondria — is not the same as mitochondrial quality, which means making the existing ones work well and clearing out the broken ones. A cell can build new mitochondria while its network is full of damaged, inefficient, or leaky ones, and simply adding more does not fix the bad units. The cell's answer to quality is a separate set of processes: mitophagy, the selective tagging and recycling of damaged mitochondria through the autophagy machinery; mitochondrial dynamics, the fusion and fission that let the network share contents and segregate damage; and the repair and turnover of mitochondrial proteins and the cardiolipin in the inner membrane. A healthy mitochondrial network depends on the balance of all of these — building, recycling, and repair held in proportion. An intervention that boosts biogenesis while quality control is failing can even be counterproductive, propagating dysfunction rather than resolving it. So the right question about any mitochondrial intervention is not just "does it make more mitochondria?" but "does it improve the function and turnover of the network?" — and the two questions have different answers for different compounds.

This framing is the right way to read the peptides and compounds that populate this space. MOTS-c is one of the more intriguing entries: it is a mitochondria-derived peptide, encoded within the mitochondrial genome itself, discovered by Pinchas Cohen and colleagues. MOTS-c acts as a signaling molecule that, among other actions, activates AMPK and can translocate to the nucleus during metabolic stress to influence the expression of stress- and metabolism-related genes. In rodent studies it has been reported to improve insulin sensitivity, enhance metabolic flexibility, and counter diet-induced and age-related metabolic decline, and because it works through AMPK it sits squarely on the biogenesis-signaling pathway. The evidence is largely preclinical; MOTS-c is a research peptide, not an approved therapy, and the human data are minimal. Its interest lies in being a genuine endogenous mitochondrial signal that engages the same sensor exercise does — but that mechanistic elegance is not a substitute for clinical proof.

NAD+ comes at the system from the SIRT1 side. NAD+ is the coenzyme whose decline with age is one of the more reproducible biochemical findings in aging research, and because SIRT1 depends on NAD+, falling NAD+ blunts the SIRT1-to-PGC-1alpha arm of biogenesis signaling. The strategy of raising NAD+ with precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — has been tested in humans, and the clearest finding is that these precursors do reliably raise blood NAD+ levels. Whether that translates into the downstream improvements in mitochondrial function and healthspan seen in animal models is still being worked out; human trials to date show some metabolic signals but have not delivered the dramatic outcomes the early mouse work suggested. NAD+ restoration is one of the more legitimately studied longevity interventions, with real human pharmacokinetic data, but it is best described as promising and under investigation rather than established.

SS-31, also known as elamipretide, addresses quality rather than quantity, which makes it a useful contrast. It is a small peptide that targets the inner mitochondrial membrane and binds cardiolipin, a lipid essential to the proper folding and function of the electron transport chain. By stabilizing cardiolipin, SS-31 is studied for its capacity to improve the efficiency of energy production and reduce the leakage of reactive oxygen species from damaged mitochondria — improving how existing mitochondria work rather than building new ones. SS-31 has advanced into human clinical trials for conditions including heart failure and primary mitochondrial diseases, which puts it further along the evidence path than most peptides discussed in longevity contexts, though results have been mixed and it is not an approved therapy. The point of including it here is the contrast it draws: MOTS-c and NAD+ act on the build-more side, SS-31 on the work-better side, and a serious account of mitochondrial health has to keep those columns separate.

So what does the evidence actually support? The honest hierarchy is clear. Exercise, particularly a combination of aerobic and high-intensity work, is the most powerful, best-validated, and most accessible driver of mitochondrial biogenesis, and it simultaneously supports quality control by stimulating mitophagy — it is the rare intervention that improves both columns at once. Caloric restriction, intermittent fasting, and adequate protein with sufficient overall energy availability support the same pathways. Cold exposure and heat exposure each engage stress responses linked to mitochondrial adaptation. Sleep and the management of chronic inflammation protect the network from accelerated damage. The compounds — MOTS-c, NAD+ precursors, SS-31 — are mechanistically coherent and worth following as the research matures, with NAD+ and SS-31 furthest along in human study, but none has displaced exercise as the foundation, and none should be approached outside a conversation with your prescribing provider, particularly given that several are research compounds not approved for human use.

The deeper lesson of mitochondrial biology is one of partnership. The bacterium that took up residence in our ancestral cell more than a billion years ago never fully became us; it kept its own DNA, its own membrane, its own logic, and it still responds to the ancient signals of feast and famine, exertion and rest. When you train, you are not merely tiring your muscles — you are sending the precise molecular message that tells these resident organelles to multiply and reinforce. That conversation between the body's demands and the mitochondria's response is older than animals themselves, and the most reliable way to keep it vigorous turns out to be the same thing that has always kept bodies capable: asking them, regularly and meaningfully, to do hard physical work.